Antiretroviral medicines Public sector: NMS is well stocked with ARV medicines above 3 MOS except EFV 600mg, ATV/r 300/100mg and LPV/r 100/25mg with less than 3 MOS. Stock is available in country for TDF/3TC/EFV 300/300/600mg (3.5 MOS), TDF/3TC/DTG 300/300/50mg (3.1 MOS), DTG 50mg (4.2 MOS), ABC/3TC 600/300mg (3.8 MOS), LPV/r 40/10mg pellets (5.2 MOS) and EFV 200mg (6.0 MOS). Transfer stock from JMS to NMS has been effected for DTG 50mg (2.2 MOS), ABC/3TC 600/300mg (2.6 MOS), EFV 200mg (2.8 MOS) and LPV/r 40/10mg pellets (1.8 MOS). Orders for ARV commodities have been placed under GF for CY 2020. Shipments for LPV/r formulations have been delayed due to the current global shortage of LPV/r. Consumption of LPV/r and ABC/3TC based formulations is expected to increase following regimen optimization for Children to LPV/r and DTG based formulations. PNFP sector: JMS is well stocked on ARV formulations (> 3MOS) except DTG 50mg and AZT/3TC 300/150mg. Shipments for AZT/3TC 300/150mg (15.8 MOS) and DTG 50mg (15.2 MOS) are expected in June 2020. There is an overstock of AZT/3TC/NVP 60/30/50mg, NVP syrup and EFV 200mg. Consumption of these commodities has reduced due to pediatric regimen optimization. At MAUL, ARV medicines are well stocked with more than 3 MOS except for LPV/r 200/50mg. A shipment of LPV/r 200/50 mg (4.3MOS) is expected by end of February 2020. An order needs to be placed by MAUL for TDF/3TC 300/300mg to avert the projected low stock levels starting in March 2020.
0 Comments